MEDIA
Latest News
Revance is a biotechnology company focused on innovative aesthetic and therapeutic offerings, as well as financial technology services for aesthetic practices.
Main Menu
- 19 August 2023
FDA approves first therapeutic indication for Daxxify for injection for the treatment of cervical dystonia
- 15 August 2023
FDA Approves Expanded Indication of DaxibotulinumtoxinA to Treat Cervical Dystonia
- 15 August 2023
Daxxify Has Just Received FDA-Approval to Treat This Painful Neck Condition
- 14 August 2023
Revance touts first therapeutic indication for Botox rival Daxxify in cervical dystonia
- 14 August 2023
Revance touts first therapeutic indication for Botox rival Daxxify in cervical dystonia
- 14 August 2023
Revance Wins First Daxxify Therapeutic Indication, Plans Limited Initial Rollout
- 14 August 2023
Revance pivots into therapeutics with cervical dystonia nod for Botox rival Daxxify
- 11 August 2023
The Secrets of Women Who Wake Up Looking Beautiful (Hint: It’s Not a Good Night’s Sleep)
- 30 June 2023